Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
October 14, 2020 17:05 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
September 10, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors

SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
September 09, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
August 12, 2020 16:01 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update

NL-201 IND submission anticipated during fourth quarter of 2020Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023Company to...
August 06, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
August 05, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020

SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
July 02, 2020 09:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
July 01, 2020 16:01 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Proposed Public Offering

SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
June 22, 2020 09:05 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

- NL-201 demonstrates durable antitumor activity in animal tumor models -- NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo -- Conditional activation of de novo...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right